EP0952841A4 - DIRECTED BIOMOLECULAR COMPLEXES - Google Patents
DIRECTED BIOMOLECULAR COMPLEXESInfo
- Publication number
- EP0952841A4 EP0952841A4 EP95929378A EP95929378A EP0952841A4 EP 0952841 A4 EP0952841 A4 EP 0952841A4 EP 95929378 A EP95929378 A EP 95929378A EP 95929378 A EP95929378 A EP 95929378A EP 0952841 A4 EP0952841 A4 EP 0952841A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- directed
- biomolecular complexes
- biomolecular
- complexes
- directed biomolecular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US286327 | 1988-12-19 | ||
| US487693 | 1990-03-02 | ||
| US08/286,327 US5716614A (en) | 1994-08-05 | 1994-08-05 | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
| US08/487,693 US6005004A (en) | 1994-08-05 | 1995-06-07 | Lipophilic-polycationic delivery systems |
| PCT/US1995/009870 WO1996004001A1 (en) | 1994-08-05 | 1995-08-04 | Site-specific biomolecular complexes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0952841A1 EP0952841A1 (en) | 1999-11-03 |
| EP0952841A4 true EP0952841A4 (en) | 2000-11-02 |
Family
ID=26963733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP95929378A Withdrawn EP0952841A4 (en) | 1994-08-05 | 1995-08-04 | DIRECTED BIOMOLECULAR COMPLEXES |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0952841A4 (en) |
| AU (1) | AU3275595A (en) |
| WO (1) | WO1996004001A1 (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US5543390A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
| GB9524807D0 (en) * | 1995-12-05 | 1996-02-07 | Smithkline Beecham Plc | Novel compounds |
| US5919815A (en) * | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| CA2297025A1 (en) * | 1997-07-25 | 1999-02-04 | Sdg, Inc. | Polymer based pharmaceutical compositions for targeted delivery of biologically active agents |
| FR2767323B1 (en) * | 1997-08-12 | 2001-01-05 | Synt Em | LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, THEIR PREPARATION AND THEIR USE FOR VECTORIZING ACTIVE SUBSTANCES |
| US6197332B1 (en) | 1997-08-13 | 2001-03-06 | Chiron Corporation | Lipid-conjugated polyamide compounds and related compositions and methods thereof |
| US6197764B1 (en) | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
| US6919076B1 (en) | 1998-01-20 | 2005-07-19 | Pericor Science, Inc. | Conjugates of agents and transglutaminase substrate linking molecules |
| US6225444B1 (en) | 1998-02-10 | 2001-05-01 | Protarga, Inc. | Neuroprotective peptides and uses thereof |
| GB9811059D0 (en) * | 1998-05-23 | 1998-07-22 | Univ Strathclyde | Polyamino acid vesicles |
| US7235583B1 (en) | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
| GB9930026D0 (en) * | 1999-12-21 | 2000-02-09 | Univ Sheffield | Novel compounds of unsaturated fatty acids |
| US7608598B2 (en) | 2000-01-10 | 2009-10-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of conjunctivitis |
| US7893226B2 (en) | 2004-09-29 | 2011-02-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Use of lipid conjugates in the treatment of diseases |
| US8304395B2 (en) | 2000-01-10 | 2012-11-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Lipid conjugates in the treatment of disease |
| US7772196B2 (en) | 2000-01-10 | 2010-08-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
| US9040078B2 (en) | 2000-01-10 | 2015-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases of the nervous system |
| US7141552B2 (en) * | 2000-01-10 | 2006-11-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
| US7811999B2 (en) | 2000-01-10 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Use of lipid conjugates in the treatment of diseases |
| US8501701B2 (en) | 2000-01-10 | 2013-08-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Use of lipid conjugates in the treatment of disease |
| US8916539B2 (en) | 2000-01-10 | 2014-12-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of disease |
| US8076312B2 (en) | 2000-01-10 | 2011-12-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Use of lipid conjugates in the treatment of disease |
| ES2328446T5 (en) | 2000-02-04 | 2014-02-27 | Children's Hospital Research Foundation | Use of lysosomal acid lipase to treat atherosclerosis and associated diseases |
| US8883761B2 (en) | 2001-01-10 | 2014-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases associated with vasculature |
| AU2002317700A1 (en) * | 2001-06-07 | 2002-12-16 | Hemebiotech A/S | Production of recombinant human arylsulfatase a |
| US7045543B2 (en) | 2001-11-05 | 2006-05-16 | Enzrel Inc. | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
| US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US7414076B2 (en) | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| WO2006085149A2 (en) | 2004-12-22 | 2006-08-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US8906882B2 (en) | 2005-11-17 | 2014-12-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Lipid conjugates in the treatment of allergic rhinitis |
| US8859524B2 (en) | 2005-11-17 | 2014-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Lipid conjugates in the treatment of chronic rhinosinusitis |
| PT2089417E (en) | 2006-10-12 | 2015-04-14 | Bhi Ltd Partnership | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
| CA2705785A1 (en) | 2006-11-14 | 2008-05-22 | Saul Yedgar | Use of lipid conjugates in the treatment of diseases or disorders of the eye |
| DE102007047246A1 (en) | 2007-09-26 | 2009-04-02 | Aesculap Ag | Reinforced vascular prosthesis with antimicrobial long-term effect |
| EP2342356A4 (en) | 2008-09-29 | 2012-11-21 | Univ Ben Gurion | BETA-AMYLOID PEPTIDES AND METHODS OF USE THEREFOR |
| JP2012526819A (en) | 2009-05-11 | 2012-11-01 | イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム リミテッド | Lipid-polymer complex, its preparation and its use |
| PT2561069T (en) | 2010-04-23 | 2017-05-22 | Alexion Pharma Inc | Lysosomal storage disease enzyme |
| CA2810999C (en) | 2010-09-09 | 2023-10-03 | Anthony Quinn | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients |
| EP2675472A4 (en) | 2011-02-15 | 2014-09-17 | Synageva Biopharma Corp | Methods for treating lysosomal acid lipase deficiency |
| CN110997693A (en) | 2017-06-07 | 2020-04-10 | 阿德克斯公司 | Tau aggregation inhibitor |
| US11453701B2 (en) | 2017-08-18 | 2022-09-27 | Adrx, Inc. | Tau aggregation peptide inhibitors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990007573A1 (en) * | 1988-12-23 | 1990-07-12 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| WO1994013311A1 (en) * | 1992-12-10 | 1994-06-23 | Enzon, Inc. | Glycolipid enzyme-polymer conjugates |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992020362A1 (en) * | 1991-05-14 | 1992-11-26 | Shashoua Victor E | Nerve growth peptides and uses therefor |
-
1995
- 1995-08-04 AU AU32755/95A patent/AU3275595A/en not_active Abandoned
- 1995-08-04 EP EP95929378A patent/EP0952841A4/en not_active Withdrawn
- 1995-08-04 WO PCT/US1995/009870 patent/WO1996004001A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990007573A1 (en) * | 1988-12-23 | 1990-07-12 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| WO1994013311A1 (en) * | 1992-12-10 | 1994-06-23 | Enzon, Inc. | Glycolipid enzyme-polymer conjugates |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO9604001A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0952841A1 (en) | 1999-11-03 |
| AU3275595A (en) | 1996-03-04 |
| WO1996004001A1 (en) | 1996-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0952841A4 (en) | DIRECTED BIOMOLECULAR COMPLEXES | |
| DK0777671T3 (en) | Spiro-azabicyclic compounds | |
| FI971260A7 (en) | 1-Acyl-4-aliphatylaminopiperidine compounds | |
| ATA166795A (en) | BIS-RESORCINYLTRIAZINE | |
| NO954458L (en) | Adhesjonsreseptorantagonister | |
| FI970151A0 (en) | Anti-virus-acting difluorostatone compounds | |
| NO20002159L (en) | Piperazine-cyclodextrin complexes | |
| DK0926953T3 (en) | Halogenpropargyline conclusion complexes | |
| FI971971A7 (en) | Pyridazinoquinoline compounds | |
| FI964532L (en) | Cross-luminescence reduction | |
| KR950024232U (en) | Improvement case | |
| KR960018679U (en) | Publication | |
| BR7400683U (en) | Odontoportable | |
| SE9403034D0 (en) | Sibab feature | |
| UA741S (en) | PLANE | |
| UA670S (en) | PLANE | |
| KR950027071U (en) | Decorative case | |
| SE9400156D0 (en) | Position | |
| KR950029395U (en) | Funeral case | |
| KR960012134U (en) | One side | |
| KR960002814U (en) | Problem | |
| PT101482A (en) | INSTRUMENTO CIRURGICO - VALVA EM LEQUE | |
| FI941280A7 (en) | Casserole | |
| FI954001A7 (en) | Casserole | |
| ATE197372T1 (en) | PRE-DOUGH |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19971118 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20000914 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
| RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 38/00 A, 7A 61K 38/18 B, 7A 61K 31/70 B, 7A 61K 39/44 B, 7A 61K 39/385 B, 7A 61K 39/395 B, 7A 61K 38/46 B |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20070301 |